Abstract
Cancer stands as one of the leading causes of death globally. Its socio-economic burden is increasing day by day. There is no defined treatment strategy for cancer. In most of the cases a combinatorial therapy approach is utilised which includes surgery, chemotherapy, immune therapy, radiation therapy etc. Immune checkpoints are a revolutionary discovery in cancer immunotherapy. Dostarlimab is an anti-programmed cell death protein-1 (PD-1) immunoglobulin G4 (IgG4) humanised monoclonal antibody (mAb), produced by recombinant DNA technology in mammalian Chinese hamster ovary (CHO) cells. PD-1 is an immune checkpoint receptor expressed by T-cells which has shown to suppress cancer-specific immune responses. In this article we provide the recent known information regarding dostarlimab along with currently undergoing 44 clinical trials globally with its title, conditions, interventions, and outcome measures.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
